LEXARIA BIOSCIENCE CORP. Accretion Expense
LEXARIA BIOSCIENCE CORP. (LEXX) reported Accretion Expense of $5.40 thousand for the 9-month period ending 2026-05-31, per its 10-Q filed 2026-07-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2026-07-13
- LEXARIA BIOSCIENCE CORP. accretion expense for the quarter ending 2026-05-31 was $1.66K, a 24.33% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. accretion expense for the quarter ending 2026-02-28 was $1.80K, a 22.56% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. accretion expense for the quarter ending 2025-11-30 was $1.94K, a 20.97% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. accretion expense for the quarter ending 2025-08-31 was $2.07K, a 76.77% increase year-over-year.
- LEXARIA BIOSCIENCE CORP. accretion expense for fiscal 2025 was $9.05K, a 35.60% increase from fiscal 2024.
- LEXARIA BIOSCIENCE CORP. accretion expense for fiscal 2024 was $6.67K.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 9 month | Accretion Expense 12 month |
|---|---|---|---|---|
| 2026-05-31 | $1.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-07-13 | $3.47K derived: sum of 2 quarters · filed 2026-07-13 | $5.40K 10-Q · filed 2026-07-13 | $7.47K derived: sum of 4 quarters · filed 2026-07-13 |
| 2026-02-28 | $1.80K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-04-13 | $3.74K 10-Q · filed 2026-04-13 | $5.81K derived: sum of 3 quarters · filed 2026-04-13 | $8.01K derived: sum of 4 quarters · filed 2026-07-13 |
| 2025-11-30 | $1.94K 10-Q · filed 2026-01-13 | $4.01K derived: sum of 2 quarters · filed 2026-01-13 | $6.21K derived: sum of 3 quarters · filed 2026-07-13 | $8.53K derived: sum of 4 quarters · filed 2026-07-13 |
| 2025-08-31 | $2.07K derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-28 | $4.27K derived: sum of 2 quarters · filed 2026-07-13 | $6.60K derived: sum of 3 quarters · filed 2026-07-13 | $9.05K 10-K · filed 2025-11-28 |
| 2025-05-31 | $2.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-07-13 | $4.53K derived: sum of 2 quarters · filed 2026-07-13 | $6.98K 10-Q · filed 2026-07-13 | $8.15K derived: sum of 4 quarters · filed 2026-07-13 |
| 2025-02-28 | $2.33K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-04-13 | $4.78K 10-Q · filed 2026-04-13 | $5.95K derived: sum of 3 quarters · filed 2026-04-13 | $8.61K derived: sum of 4 quarters · filed 2026-04-13 |
| 2024-11-30 | $2.45K 10-Q · filed 2026-01-13 | $3.62K derived: sum of 2 quarters · filed 2026-01-13 | $6.28K derived: sum of 3 quarters · filed 2026-01-13 | $9.06K derived: sum of 4 quarters · filed 2026-01-13 |
| 2024-08-31 | $1.17K derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-28 | $3.83K derived: sum of 2 quarters · filed 2025-11-28 | $6.61K derived: sum of 3 quarters · filed 2025-11-28 | $6.67K 10-K · filed 2025-11-28 |
| 2024-05-31 | $2.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-07-14 | $5.43K derived: sum of 2 quarters · filed 2025-07-14 | $5.50K 10-Q · filed 2025-07-14 | |
| 2024-02-29 | $2.77K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-04-14 | $2.84K 10-Q · filed 2025-04-14 | ||
| 2023-11-30 | $67.00 10-Q · filed 2025-01-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |